Aclaris Therapeutics (ACRS) Non-Current Assets (2017 - 2025)
Historic Non-Current Assets for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $74.9 million.
- Aclaris Therapeutics' Non-Current Assets rose 4969.24% to $74.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $343.6 million, marking a year-over-year increase of 7111.96%. This contributed to the annual value of $94.4 million for FY2024, which is 3767.67% up from last year.
- Per Aclaris Therapeutics' latest filing, its Non-Current Assets stood at $74.9 million for Q3 2025, which was up 4969.24% from $84.9 million recorded in Q2 2025.
- Aclaris Therapeutics' Non-Current Assets' 5-year high stood at $102.7 million during Q2 2023, with a 5-year trough of $11.1 million in Q3 2022.
- Moreover, its 5-year median value for Non-Current Assets was $46.8 million (2021), whereas its average is $55.5 million.
- In the last 5 years, Aclaris Therapeutics' Non-Current Assets plummeted by 8083.76% in 2022 and then surged by 76161.5% in 2023.
- Aclaris Therapeutics' Non-Current Assets (Quarter) stood at $46.2 million in 2021, then tumbled by 50.09% to $23.0 million in 2022, then surged by 197.44% to $68.5 million in 2023, then skyrocketed by 37.68% to $94.4 million in 2024, then dropped by 20.59% to $74.9 million in 2025.
- Its Non-Current Assets stands at $74.9 million for Q3 2025, versus $84.9 million for Q2 2025 and $89.3 million for Q1 2025.